Chlorogenic acid attenuates high mobility group box 1 (HMGB1) and enhances host defense mechanisms in murine sepsis

Molecular Medicine

Volumn 18, Issue 11, 2012, Pages 1437-1448

  Lee, Chan Ho ^a   Yoon, Seong Jin ^a   Lee, Sun Mee ^a  

^a Sungkyunkwan University   (South Korea)

Author keywords

[No Author keywords available]

Indexed keywords

CHLOROGENIC ACID; GAMMA INTERFERON; HIGH MOBILITY GROUP B1 PROTEIN; IMMUNOGLOBULIN ENHANCER BINDING PROTEIN; INTERCELLULAR ADHESION MOLECULE 1; INTERLEUKIN 10; INTERLEUKIN 12; INTERLEUKIN 1BETA; INTERLEUKIN 2; INTERLEUKIN 6; MESSENGER RNA; MITOGEN ACTIVATED PROTEIN KINASE P38; MONOCYTE CHEMOTACTIC PROTEIN 1; PROTEIN C JUN; TOLL LIKE RECEPTOR 4; TUMOR NECROSIS FACTOR ALPHA;

ANIMAL CELL; ANIMAL EXPERIMENT; ANIMAL MODEL; ANIMAL TISSUE; ANTIBACTERIAL ACTIVITY; ARTICLE; BACTEREMIA; BACTERIAL CLEARANCE; CONTROLLED STUDY; CYTOKINE RELEASE; DEFENSE MECHANISM; DOWN REGULATION; DRUG EFFECT; DRUG MECHANISM; ENDOTOXEMIA; ENZYME ACTIVATION; ENZYME PHOSPHORYLATION; FLOW CYTOMETRY; GENE; GENE EXPRESSION REGULATION; HOST RESISTANCE; IN VIVO STUDY; MALE; MOUSE; NONHUMAN; ORGAN INJURY; PERITONEUM MACROPHAGE; PRIORITY JOURNAL; PROTEIN EXPRESSION; PROTEIN FUNCTION; SEPSIS; SIGNAL TRANSDUCTION; TH1 CELL; TOLL LIKE RECEPTOR 4 GENE; UPREGULATION;

ANIMALS; APOPTOSIS; CECUM; CHEMOKINES; CHLOROGENIC ACID; ENDOTOXEMIA; HMGB1 PROTEIN; HOST-PATHOGEN INTERACTIONS; IMMUNITY; INFLAMMATION; INTERCELLULAR ADHESION MOLECULE-1; LIGATION; LIPOPOLYSACCHARIDES; MACROPHAGES, PERITONEAL; MALE; MICE; PUNCTURES; SEPSIS; SIGNAL TRANSDUCTION; SURVIVAL ANALYSIS; TOLL-LIKE RECEPTOR 4;

EID: 84872224514     PISSN: 10761551     EISSN: None     Source Type: Journal    
DOI: 10.2119/molmed.2012.00279     Document Type: Article

References (48)

1. Hotchkiss RS, Karl IE. (2003) The pathophysiology and treatment of sepsis. N. Engl. J. Med. 348:138-50.
2. Wang H, et al. (1999) HMG-1 as a late mediator of endotoxin lethality in mice. Science. 285:248-51.
3. Riedemann NC, Guo RF, Ward PA. (2003) The enigma of sepsis. J. Clin. Invest. 112:460-7.
4. Niggeweg R, Michael AJ, Martin C. (2004) Engineering plants with increased levels of the antioxidant chlorogenic acid. Nat. Biotechnol. 22:746-54.
5. Stoclet JC, et al. (2004) Vascular protection by dietary polyphenols. Eur. J. Pharmacol. 500:299-313.
6. Olmos A, et al. (2007) Effects of plant alkyl-phenols on cytokine production, tyrosine nitration and inflammatory damage in the efferent phase of contact hypersensitivity. Br. J. Pharmacol. 152:366-73.
7. Zhang X, et al. (2010) Chlorogenic acid protects mice against lipopolysaccharide-induced acute lung injury. Injury. 41:746-52.
8. Xu Y, et al. (2010) Protective effects of chlorogenic acid on acute hepatotoxicity induced by lipo-poly saccharide in mice. Inflamm. Res. 59:871-7.
9. Feng R, et al. (2005) Inhibition of activator protein-1, NF-kappaB, and MAPKs and induction of phase 2 detoxifying enzyme activity by chlorogenic acid. J. Biol. Chem. 280:27888-95.
10. Cho ES, et al. (2009) Attenuation of oxidative neuronal cell death by coffee phenolic phytochemicals. Mutat. Res. 661:18-24.
11. Institute of Laboratory Animal Resources; Commission on Life Sciences; National Research Council. (1996) Guide for the Care and Use of Laboratory Animals. Washington (DC): National Academy Press. [cited 2012 Mar 15]. Available from: http://www.nap.edu/openbook. php? record_id=5140
12. Rittirsch D, Huber-Lang MS, Flierl MA, Ward PA. (2009) Immunodesign of experimental sepsis by cecal ligation and puncture. Nat. Protoc. 4:31-6.
13. Ulloa L, et al. (2002) Ethyl pyruvate prevents lethality in mice with established lethal sepsis and systemic inflammation. Proc. Natl. Acad. Sci. U. S. A. 99:12351-6.
14. Chomczynski P, Sacchi N. (1987) Single-step method of RNA isolation by acid guanidinium thiocyanate-phenol-chloroform extraction. Anal. Biochem. 162:156-9.
15. Freire-Garabal M, et al. (2002) Effects of fluoxetine on the activity of phagocytosis in stressed mice. Life Sci. 72:173-83.
16. Ding AH, Nathan CF, Stuehr DJ. (1988) Release of reactive nitrogen intermediates and reactive oxygen intermediates from mouse peritoneal macrophages: comparison of activating cytokines and evidence for independent production. J. Immunol. 141:2407-12.
17. Buras JA, Holzmann B, Sitkovsky M. (2005) Animal models of sepsis: setting the stage. Nat. Rev. Drug Discov. 4:854-65.
18. Yang H, et al. (2004) Reversing established sepsis with antagonists of endogenous high-mobility group box 1. Proc. Natl. Acad. Sci. U. S. A. 101:296-301.
19. Park JS, et al. (2004) Involvement of toll-like receptors 2 and 4 in cellular activation by high mobility group box 1 protein. J. Biol. Chem. 279:7370-7.
20. Williams DL, et al. (2003) Modulation of tissue Toll-like receptor 2 and 4 during the early phases of polymicrobial sepsis correlates with mortality. Crit. Care Med. 31:1808-18.
21. Rittirsch D, Flierl MA, Ward PA. (2008) Harmful molecular mechanisms in sepsis. Nat. Rev. Immunol. 8:776-87.
22. Ebersole JL, Cappelli D. (2000) Acute-phase reactants in infections and inflammatory diseases. Periodontol. 2000 23:19-49.
23. Heremans H, Dillen C, Put W, Van Damme J, Billiau A. (1992) Protective effect of anti-interleukin (IL)-6 antibody against endotoxin, associated with paradoxically increased IL-6 levels. Eur. J. Immunol. 22:2395-401.
24. Kishimoto T. (1989) The biology of interleukin-6. Blood. 74:1-10.
25. Czura CJ, Tracey KJ. (2003) Targeting high mobility group box 1 as a late-acting mediator of inflammation. Crit. Care Med. 31:S46-50.
26. Li W, et al. (2007) A cardiovascular drug rescues mice from lethal sepsis by selectively attenuating a late-acting proinflammatory mediator, high mobility group box 1. J. Immunol. 178:3856-64.
27. Scaffidi P, Misteli T, Bianchi ME. (2002) Release of chromatin protein HMGB1 by necrotic cells triggers inflammation. Nature. 418:191-5.
28. Salvemini D, Cuzzocrea S. (2003) Therapeutic potential of superoxide dismutase mimetics as therapeutic agents in critical care medicine. Crit. Care Med. 31:S29-38.
29. Sessler CN, et al. (1995) Circulating ICAM-1 is increased in septic shock. Am. J. Respir. Crit. Care Med. 151:1420-7.
30. Muller Kobold AC, et al. (2000) Leukocyte activation in sepsis; correlations with disease state and mortality. Intensive Care Med. 26:883-92.
31. Yu M, et al. (2006) HMGB1 signals through tolllike receptor (TLR) 4 and TLR2. Shock. 26:174-9.
32. Karin M, Ben-Neriah Y. (2000) Phosphorylation meets ubiquitination: the control of NF-mB activity. Annu. Rev. Immunol. 18:621-63.
33. Kopp EB, Medzhitov R. (1999) The Toll-receptor family and control of innate immunity. Curr. Opin. Immunol. 11:13-8.
34. Akira S, Takeda K. (2004) Toll-like receptor signalling. Nat. Rev. Immunol. 4:499-511.
35. van Zoelen MA, et al. (2009) Role of toll-like receptors 2 and 4, and the receptor for advanced glycation end products in high-mobility group box 1-induced inflammation in vivo. Shock. 31:280-4.
36. Yang H, et al. (2010) A critical cysteine is required for HMGB1 binding to toll-like receptor 4 and activation of macrophage cytokine release. Proc. Natl. Acad. Sci. U. S. A. 107:11942-7.
37. McCloskey CA, Kameneva MV, Uryash A, Gallo DJ, Billiar TR. (2004) Tissue hypoxia activates JNK in the liver during hemorrhagic shock. Shock 22:380-6.
38. Abbas AK, Murphy KM, Sher A. (1996) Functional diversity of helper T lymphocytes. Nature. 383:787-93.
39. Weighardt H, et al. (2002) Impaired monocyte IL-12 production before surgery as a predictive factor for the lethal outcome of postoperative sepsis. Ann. Surg. 235:560-7.
40. Heidecke CD, et al. (1999) Selective defects of T lymphocyte function in patients with lethal intraabdominal infection. Am. J. Surg. 178:288-92.
41. Fiuza C, et al. (2003) Inflammation-promoting activity of HMGB1 on human microvascular endothelial cells. Blood. 101:2652-60.
42. Yan SF, et al. (2000) Egr-1, a master switch coordinating upregulation of divergent gene families underlying ischemic stress. Nat. Med. 6:1355-61.
43. Ping D, et al. (2000) Sp1 binding is critical for promoter assembly and activation of the MCP-1 gene by tumor necrosis factor. J. Biol. Chem. 275:1708-14.
44. Yoshimura T, Leonard EJ. (1991) Human monocyte chemoattractant protein-1 (MCP-1). Adv. Exp. Med. Biol. 305:47-56.
45. Standiford TJ, Kunkel SL, Greenberger MJ, Laichalk LL, Strieter RM. (1996) Expression and regulation of chemokines in bacterial pneumonia. J. Leukoc. Biol. 59:24-8.
46. Huber-Lang MS, et al. (2002) Complementinduced impairment of innate immunity during sepsis. J. Immunol. 169:3223-31.
47. Czermak BJ, et al. (1999) Protective effects of C5a blockade in sepsis. Nat. Med. 5:788-92.
48. Ward PA. (2008) Sepsis, apoptosis and complement. Biochem. Pharmacol. 76:1383-8.